Mycoplasma gallisepticum has three virulence genes (mgc1, mgc2 and mgc3), and Mycoplasma synoviae has adhesion gene (vlhA). These genes are responsible for adhesion and colonization of the respiratory tract of the host. Therefore, this study was concerned with preparation of recombinant vaccine from field isolates which was compared with membrane and whole cells vaccines. The virulence genes were cloned into plasmid vectors followed by transformation into E. coli BL-21competent cells for the expression of adhesion proteins.
Introduction
Mycoplasma gallisepticum causes severe economic losses to the poultry industry. Considering that eradication through elimination of positive flocks is expensive, available vaccines do not protect against infection, and the disease is difficult to effectively treat, new alternatives are needed to control the disease [1] .
M. synoviae and M. gallisepticum are avian pathogens that can both cause respiratory disturbances. In addition, M. gallisepticum infection can lead to egg production losses and M. synoviae causes articular troubles [1] . Mycoplasmas have oval, filamentous or flask shapes, and several pathogenic species display a prominent polar tip organelle or bleb structure that mediates attachment to the host target cells. With the aid of the products of the gapA(or mgc1) gene [2, 3] and crmA or mgc3 [4] . This tip structure is hemispherical, around 800x1250 A in circumferences and composed of surface-exposed proteins, called adhesins or cytadhesions proteins. These adhesions promote the attachment of mycoplasma allowing the colonization of epithelial cell surfaces [5, 6] .
M. synoviae is a pathogen associated with osteoarthritis, synovitis, and respiratory tract lesions of poultry [7] .Cytadherence mediated by its primary adhesion vlhA that is a precursor to virulence. Posttranslational cleavage of fulllength vlhA produces the peptides MSPA (carboxy-terminal portion of vlhA) and MSPB As a consequence, recombinant technology could significantly help to alleviate the above mentioned drawbacks, allowing the production of unlimited amounts of multiple and more specific antigens [9] . Although identification of immunogenic antigens and genetic manipulations of mycoplasma in general are more laborious than any other prokaryotic genome, it is vital to successfully express M. gallisepticum proteins in heterologous systems such as E. coli [10] .
Therefore, the present work aimed to prepare M. gallisepticum and M. synoviae recombinant vaccine to control mycoplasma infection in layers and breeders. 
Materials and Methods

Mycoplasma strains
Preparation of mycoplasma antigens
Mycoplasma antigens were prepared according to Frey et al. [13] . M. gallisepticum 3 and M. synoviae were grown in Frey's media for 48 hours and harvested by centrifugation at 14000 rpm for 20 min. The pellet was washed three times with phosphate buffered saline (PBS), pH 7.2, then re-suspended in PBS and the protein concentration was estimated as previously described [14] .
Membrane protein extraction
It was carried out using ProteoJET, Fermentas, cat. No. 89842X according to the manufacturers' instructions.
Preparation of recombinant vaccine
The vaccine was prepared according to Griffin, 1949 Expression of fusion proteins were induced by the addition of 1 mmol/L IPTG on Lysogeny broth and incubated at 37•C for 12 h, then purified on a Nickel -NTA column (HisPur Ni-NTA columns, Thermo scientific, cat. No. 88225). The purified proteins were used for vaccine preparation.
Vaccine evaluation
Determination of Hydrophilic-Lipophilic Balance (HLB) value of the oil emulsion according to Cessi and Nardelli [16] and WHO [17] .
Physical evaluation
Emulsion stability test was conducted using specification [18] . The Viscosity testing was carried out according to Cessi and Nardelli [16] . In brief, each 100 mL of the vaccine containing 9.7 mL span 80 (Sigma), 59 mL paraffin oil (Sigma) as oil phase, 1.8 mL tween 80 (sigma) and 29.5 mL PBS (1mg/mL membrane protein) as aqueous phase to prepare the vaccine.
Sterility testing
It was applied according to the Code of Federal Regulations "9 CFR" for detection of Bacteria, Fungi and Mycoplasma contamination.
Safety and potency test:
The challenge test was carried out according to Nicholas et al. [18].
Experimental design
Fifty female 85 days old commercial layers (ISA-Brown) were housed in cleaned, fumigated and well ventilated rooms in the central laboratory, Animal Health Research Institute, Dokki, Giza, Egypt. They were acclimatized for 2 days before the onset of the experiment. Non-medicated feed and water were provided. All Institutional and National Guidelines for the care and use of animals were followed. No. 96-6536Synbiotics, USA) and PCR tests to confirm that the birds were control for avian Mycoplasma. The birds were divided into 7 groups (5 birds for each); vaccinated with (M. gallisepticum recombinant (MGR), MG membrane (MGM), MG with M. synoviae recombinant (MSR), MG plus M. synoviae membrane (MSM), M gallisepticum whole cell (MGW), MGW with a M. synoviae whole cell (MSW) and non vaccinated control group. All vaccinated groups were kept in isolated unit away from the vaccinated groups. Throughout the study, birds were provided with feed and water and vitamins. The vaccines were given at two weeks old, with the corresponding vaccine for each vaccinated group with first dose (100 µg/mL subcutaneous), then received the second dose two weeks later. After two weeks the second dose was applied with same route and dose. After two weeks, all the nine vaccinated groups were challenged with the corresponding hot field strain of M. gallisepticum and M. synoviae (10 6 CFU/mL). Every two weeks blood samples, Eggs and tracheal swabs were collected till the end of experiment. Figure (1) . The different genes were purified and sequenced. The sequence analysis of the field strains were compared with the reference strains on GenBank Data base and showed 100% similarity. Tracheal swabs that had turned yellow on Frey's broth were subjected to DNA extraction and tested by PCR test for the detection of M. gallisepticum and M. synoviae using specific primers.
As depicted in Table ( For both serum and egg yolk, all vaccinated groups had significantly higher means than the non vaccinated group at p< 0.05. Table ( 3) shows the geometric mean titers (GMTs) of M. synoviae in serum and egg yolk. The results proved that there were no significant differences between the GMTs of the vaccinated groups, but all vaccinated groups were significantly different from the control group at p< 0.05. Concerning PCR and culture, MGR, MG and MSR vaccinated groups were negative from the first week post-challenge and continued till the end of experiment. While 
Discussion
M. gallisepticum (R low passage strain) is pathogenic for chickens, colonizing the trachea (during in vivo assays) and producing air sac and tracheal lesions due to presence of gapA and crmA genes. In contrast, R high strains required 4 orders of magnitude for more organisms to colonize air sacs and tracheas to produce detectable lesions [20] .Also it was mentioned that mgc2 gene is incorporated in cytadherence, virulence and post infection autoimmunity [21] . For M.synoviae, it was reported that vlhA gene is a precursor of virulence [8] . In the present study we detected the three virulence genes of M. gallisepticum (gapA, crmA and mgc2) and vlhA gene of M. synoviae in our field strains. The purified genes were used for cloning in plasmid vector and expression in E. coli competent cells. The resulted recombinant proteins were used for preparation of recombinant vaccine. Also MG and MS membrane and whole cell bacterin were prepared. The obtained results proved that the recombinant vaccine can replace the other MG and MS vaccine due to good protection and healthy condition of vaccinated groups even after challenge with the virulent field strains. Besides the positive antibody titer two weeks post-vaccination and increased till the end of experiment. The results showed no significant differences among the vaccinated groups, while there was difference when compared with control negative group.
After challenge of the all vaccinated groups with MG and MS field strain, the recombinant vaccinated groups proved to be negative for PCR even at the end of experiment. On the other hand, membrane and whole cell vaccinated group showed positive PCR results.
In membrane vaccinated chickens, the antibody levels remained the same as after the challenge and the bacterin vaccinated group showed the highest titer during the entire experiment. This was found to be in agreement with Moura et al. [22] who mentioned that all vaccinated groups gave higher antibody titers and with El-Shater et al. [23] who concluded that vaccination of chickens with M. gallisepticum subunit vaccine resulted in high antibody response at two weeks after the booster dose.
Concerning the MS vaccinated groups; recombinant vaccinated groups gave weak positive results, while membrane and whole cell vaccinated groups were positive. Trials for re-isolation of Mycoplasma from different vaccinated groups after challenge were done. MG and MG and MS recombinant vaccinated groups and control group were negative during the experimental period, while membrane and whole cell vaccinated groups were positive, this coincides with El-Shater et al. [23] who concluded that M. gallisepticum subunit vaccine show humoral immunity but didn't give protection against infection, indicating 
Conclusion
The obtained results proved that the locally prepared MG and MS recombinant vaccine from local field isolates was the best choice for vaccination and protection of the commercial layers against mycoplasma infection in comparison with membrane and whole cell vaccines.
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